Shafique Virani - Feb 15, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Business Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Feb 15, 2023
Transactions value $
-$66,922
Form type
4
Date filed
2/17/2023, 04:13 PM
Previous filing
Feb 3, 2023
Next filing
May 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $16.6K +7.49K +3.94% $2.22* 197K Feb 15, 2023 Direct F1
transaction RXRX Class A Common Stock Sale -$62.4K -7.49K -3.79% $8.33 190K Feb 15, 2023 Direct F1
transaction RXRX Class A Common Stock Tax liability -$6.3K -746 -0.39% $8.44 189K Feb 15, 2023 Direct F2
transaction RXRX Class A Common Stock Sale -$14.9K -1.77K -0.93% $8.42 187K Feb 16, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 +7.49K +1.2% $0.00 629K Feb 15, 2023 Class A Common Stock 7.49K $2.22 Direct F1, F4
holding RXRX Stock Option (Right to Buy) 213K Feb 15, 2023 Class A Common Stock 0 $8.55 Direct F3
holding RXRX Stock Option (Right to Buy) 80.5K Feb 15, 2023 Class A Common Stock 0 $11.40 Direct F5
holding RXRX Stock Option (Right to Buy) 5.44K Feb 15, 2023 Class A Common Stock 0 $11.40 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person
F2 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F3 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F4 One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.